Post-marketing safety experience of vedolizumab in older patients with inflammatory bowel disease

Autor: Travis, S, Ungaro, R, Blake, A, Bhayat, F, Card, T

Vedolizumab is a gut-selective antibody to α4β7 integrin approved for the treatment of moderate to severe ulcerative colitis (UC) and Crohn’s disease (CD) in adult patients. Only 3% of patients in pivotal trials of vedolizumab were aged 65–80 y

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1064::6b765c788c032e8042dcc0321cabe048
https://ora.ox.ac.uk/objects/uuid:b8f7c7b8-a0fd-4fca-a419-0845ea0a8b23

Post-marketing experience of vedolizumab: Pneumonia and other respiratory tract infections

Autor: Bhayat, F, Blake, A, Travis, S

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1064::38ce2ae34bcda4db2c729f6be2ded7b2
https://ora.ox.ac.uk/objects/uuid:9f3ab08e-c2c6-41dd-a5be-731268e95d63

Dynamic Presentations of Recurrent Post-Transplant Lymphoproliferative Disorder in a Heart Transplant Recipient: A Rare Case Study.

Autor: Toiv, Avi¹ atoiv1@hfhs.org, Harris, Kevin B.², Khan, Muhammad Zarrar², Theisen, Brian K.³, Varma, Adarsh², Fain, Christopher², Kaur, Nirmal²

Publikováno v: ACG Case Reports Journal. Nov2024, Vol. 11 Issue 11, p1-4. 4p.

The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data.

Autor: Cohen RD; Department of Medicine, Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, IL, USA., Bhayat F; Takeda Pharmaceuticals International Co., Global Patient Safety, Cambridge, MA, USA., Blake A; Takeda Pharmaceuticals International Co., Global Patient Safety, Cambridge, MA, USA., Travis S; Translational Gastroenterology Unit, National Institute for Health Research Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK.

Publikováno v: Journal of Crohn's & colitis [J Crohns Colitis] 2020 Feb 10; Vol. 14 (2), pp. 192-204.

Risques des associations thérapeutiques.

Autor: Altwegg, Romain¹ (AUTHOR) r-altwegg@chu-montpellier.fr

Publikováno v: Hépato-Gastro & Oncologie Digestive. Oct2024, Vol. 31 Issue 8, p828-833. 6p.